Release date: 2026-01-08 10:29:43 Recommended: 155
Ixazomib is a proteasome inhibitor, and its mechanism of action helps kill cancer cells.
Concurrent use of this product with any of the following drugs is generally not recommended, but it may still be necessary in certain cases. If co-administration is indeed required, physicians may adjust the dosage or administration frequency of one or both drugs.
The involved drugs include abrocitinib, live attenuated adenovirus type 4 vaccine, live attenuated adenovirus type 7 vaccine, apalutamide, avacopan, carbamazepine, cholera vaccine, clarithromycin, conivaptan, live attenuated Zaire ebolavirus vaccine, enzalutamide, fedratinib, fexinidazole, fosphenytoin, live attenuated influenza vaccine, itraconazole, letermovir, mifepristone, mitotane, omarigliptin, phenobarbital, phenytoin, primidone, rifampicin, live attenuated rotavirus vaccine, St. John's wort, tazemetostat, and voriconazole.
Certain drugs should be avoided during meals or under specific dietary conditions, as interactions may occur otherwise. Concurrent alcohol consumption or smoking may also trigger interactions. Please discuss the precautions for using this product with food, alcohol, or tobacco with your healthcare provider.
Other health conditions may affect the use of this product. Be sure to inform your physician if you have any other diseases.
1. Heart disease.
2. Peripheral neuropathy (nerve disorders).
3. Thrombocytopenia (low platelet count).
1. Severe renal disease.
2. Moderate to severe hepatic disease.